CNR2 and glioblastoma: This study introduces a novel approach by evaluating SMA-WIN’s enhanced cytotoxicity and subtype-specific receptor modulation (CB1, CB2, TRPV1, PPAR-γ) in epithelial (LN18) and mesenchymal (A172) GBM cell lines, with a particular focus on PPAR-γ’s role in mesenchymal subtypes.